$37.5 million investment in Austrian vaccines developer Themis Bioscience

8 March 2018

A new partnership between Austrian biotech Themis Bioscience and Oslo-based CEPI – the Coalition for Epidemic Preparedness Innovations – will see an investment of up to $37.5 million going into vaccine development and manufacturing for Lassa fever and MERS.

Since its foundation, CEPI has secured almost half a billion dollars from the governments of Norway, Japan and Germany, the Wellcome Trust and the Bill and Melinda Gates Foundation.

The deal, which will fund Themis’ development projects for five years, represents the first company agreement that CEPI has signed since it was established in 2017 to finance new vaccines to prevent and contain infectious disease epidemics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK